This is a matter for the US Government. The UK's position on Jerusalem is that the status of Jerusalem should be determined in a negotiated settlement, and ultimately the shared capital of both states.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4210", "label" : {"_value" : "Biography information for Lord Ahmad of Wimbledon"} } , "answeringMemberPrinted" : {"_value" : "Lord Ahmad of Wimbledon"} , "dateOfAnswer" : {"_value" : "2021-11-05", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-11-05T13:40:20.437Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "208"} , "answeringDeptShortName" : {"_value" : "Foreign, Commonwealth and Development Office"} , "answeringDeptSortName" : {"_value" : "Foreign, Commonwealth and Development Office"} , "date" : {"_value" : "2021-10-22", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Jerusalem: USA"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what assessment they have made of the proposal by the government of the United States of America to reopen their consulate in East Jerusalem.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2018", "label" : {"_value" : "Biography information for Lord Hylton"} } , "tablingMemberPrinted" : [{"_value" : "Lord Hylton"} ], "uin" : "HL3346"} , {"_about" : "http://data.parliament.uk/resources/1189829", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1189829/answer", "answerText" : {"_value" : "
As of 15 May, over 13,000 businesses have contacted the Government with offers of help on supplying personal protective equipment (PPE). Many are related to the manufacture of PPE for the National Health Service and care sectors, a vast majority of which we are taking forward, predominantly from United Kingdom based companies but also including multinational companies. Some offers were not progressed due to financial and capability considerations.<\/p>
The Department engages directly with potential manufacturers to qualify and prioritise the opportunity, based on availability of and access to raw supplies, lead-times to manufacture, and other commercial considerations. Product prototypes are submitted to a Technical Product Review process, to ensure they meet essential health, safety and quality standards for PPE. Financial due diligence and fraud prevention measures are also undertaken, after which the Department can contract with the manufacturer.<\/p>
<\/p>
Lord Deighton is leading the Government\u2019s efforts to secure sufficient PPE and ensure this gets to where it is needed. He is also driving forward coordination of the end-to-end process design and manufacture of new domestic PPE supplies. As at 15 May, the Department has entered into contract and placed orders with eight manufacturers to provide millions of items of PPE products to the National Health Service and carers. The volumes will increase in the coming weeks.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4708", "label" : {"_value" : "Biography information for Lord Bethell"} } , "answeringMemberPrinted" : {"_value" : "Lord Bethell"} , "dateOfAnswer" : {"_value" : "2020-05-27", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2020-05-27T11:47:09.76Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2020-04-21", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS: Protective Clothing"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government whether all suppliers and potential providers of personal protective equipment within the UK have been used by the NHS.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1796", "label" : {"_value" : "Biography information for Lord Taylor of Warwick"} } , "tablingMemberPrinted" : [{"_value" : "Lord Taylor of Warwick"} ], "uin" : "HL3346"} , {"_about" : "http://data.parliament.uk/resources/792394", "AnsweringBody" : [{"_value" : "Department for Transport"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/792394/answer", "answerText" : {"_value" : "
In 2016 Atkins, on behalf of the Department for Transport, undertook analysis on the business case for electrification and other route enhancements of the Midland Main Line route from Bedford north to Corby, Leicester, Nottingham and Sheffield. A copy of this is in the House library; Chapter 3 (pp 17-24) has the required timings for those journeys.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4584", "label" : {"_value" : "Biography information for Baroness Sugg"} } , "answeringMemberPrinted" : {"_value" : "Baroness Sugg"} , "dateOfAnswer" : {"_value" : "2017-12-04", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-12-04T17:32:49.293Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "27"} , "answeringDeptShortName" : {"_value" : "Transport"} , "answeringDeptSortName" : {"_value" : "Transport"} , "date" : {"_value" : "2017-11-20", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Railways: Sheffield"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government, in preparation for the re-letting of the East Midlands Train franchise, what estimate they have made of the overall journey times for (1) a bi-mode train, and (2) an electric alternative, between London and Sheffield.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2483", "label" : {"_value" : "Biography information for Lord Bradshaw"} } , "tablingMemberPrinted" : [{"_value" : "Lord Bradshaw"} ], "uin" : "HL3346"} , {"_about" : "http://data.parliament.uk/resources/638595", "AnsweringBody" : [{"_value" : "HM Treasury"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/638595/answer", "answerText" : {"_value" : "
The Government maintains close and constructive links with charity sector representatives and is in regular dialogue with the sector. HM Revenue and Customs has set up an outreach team which is particularly focused on responding to the needs of smaller charities.<\/p>
This team regularly makes visits to small charities and has provided face-to-face presentations to over 650, raising awareness and helping charities to receive support through the Gift Aid Small Donations Scheme, as well as the full range of available tax reliefs to which they are entitled.<\/p>
<\/p>
Amounts claimed under the Gift Aid Small Donations Scheme since 2013 are £6 million in 2013/14, £21 million in 2014/15 and £26 million in 2015/16. Figures for 2016/17 are not currently available.<\/p>
<\/p>
The costs of administering the Gift Aid Small Donations Scheme and instances of malpractice are not available as they are included in the figures for the wider Gift Aid scheme, and cannot be separately extracted.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/57", "label" : {"_value" : "Biography information for Lord Young of Cookham"} } , "answeringMemberPrinted" : {"_value" : "Lord Young of Cookham"} , "dateOfAnswer" : {"_value" : "2016-12-02", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "HL3347"} , {"_value" : "HL3348"} , {"_value" : "HL3349"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2016-12-02T14:18:07.357Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "14"} , "answeringDeptShortName" : {"_value" : "Treasury"} , "answeringDeptSortName" : {"_value" : "CaTreasury"} , "date" : {"_value" : "2016-11-18", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Gift Aid Small Donations Scheme"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government how much money has been claimed under the Small Charitable Donations Act 2012 in each year since 2013.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2501", "label" : {"_value" : "Biography information for Baroness Barker"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Barker"} ], "uin" : "HL3346"} , {"_about" : "http://data.parliament.uk/resources/426407", "AnsweringBody" : [{"_value" : "Department for Transport"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/426407/answer", "answerText" : {"_value" : "
Road safety education includes a range of interventions including educational courses and publicity campaigns.<\/p>
The Department funds the THINK! road safety publicity campaign. We evaluate the campaign to ensure it is effective, that we continually improve performance; and that we ultimately deliver value for money for the taxpayer.<\/p>
Prior to each campaign we set communication objectives and key performance indicators. We measure progress against these by running surveys with our target audience before and immediately after the campaign. We have seen positive shifts in key performance indicators for the majority of our campaigns. All of our recent campaign evaluation reports are published on gov.uk[1]<\/sup><\/sup>.<\/p> In the long run, positive changes in key performance indicators on campaigns such as speeding, drink driving and seatbelts have correlated with fewer drivers exceeding the speed limit, fewer accidents involving drink driving and higher seatbelt wearing rates; and ultimately to fewer road casualties.<\/p> Publicity campaigns are part of the solution to reduce road casualties and work best when used alongside enforcement and engineering interventions. Due to the multiple factors affecting casualties (weather, road conditions, traffic levels, the economy etc.) it is difficult to demonstrate a causal relationship with a specific intervention. However, in 2012 the department commissioned an independent agency to evaluate the impact drink drive campaigns have had on casualties. They used econometric modelling to estimate that over a 30 year period, drink drive communication campaigns have saved almost 2,000 lives and prevented over 10,000 serious injuries[2]<\/sup><\/sup>.<\/p> In 2013, the Transport Research Laboratory published[3]<\/sup><\/sup> a review and synthesis of evidence on the effectiveness of pre-driver education and training for those under 17 years of age which was undertaken for the Coalition Government. The findings showed that very few interventions had been robustly evaluated and that the evidence base around pre-driver interventions was weak. The Government recently commissioned an evidence base review, to build on existing work, to help us to understand the effectiveness of a range of pre- and post-test behavioural and technological interventions for young drivers. The Government is currently also funding an evaluation of the effectiveness of speed awareness courses.<\/p> [1]<\/sup><\/sup> https://www.gov.uk/government/collections/think-communication-activity<\/p> [2]<\/sup><\/sup> https://www.gov.uk/government/publications/drink-drive-30-years-of-communication<\/p> [3]<\/sup><\/sup> https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/249282/novice-driver-research-findings.pdf<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4210", "label" : {"_value" : "Biography information for Lord Ahmad of Wimbledon"}
}
, "answeringMemberPrinted" : {"_value" : "Lord Ahmad of Wimbledon"}
, "dateOfAnswer" : {"_value" : "2015-11-17", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-11-17T12:47:08.653Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "27"}
, "answeringDeptShortName" : {"_value" : "Transport"}
, "answeringDeptSortName" : {"_value" : "Transport"}
, "date" : {"_value" : "2015-11-05", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Roads: Safety"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government what assessment they have made of the effectiveness of road safety awareness educational programmes in reducing accidents.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/3801", "label" : {"_value" : "Biography information for Lord Browne of Belmont"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Browne of Belmont"}
], "uin" : "HL3346"}
, {"_about" : "http://data.parliament.uk/resources/167245", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/167245/answer", "answerText" : {"_value" : " Products used in direct-to-consumer testing services providing health-related information are regulated as in vitro<\/em> diagnostic medical devices and are subject to European Union legislation that sets out minimum standards of safety and quality. The testing service itself is not subject to this legislation, only the products.<\/p> <\/p> <\/p> <\/p> Manufacturers of in vitro<\/em> diagnostic medical devices are required to register with the competent authority in the country where they are placing the device on the market. In the United Kingdom this is the Medicines and Healthcare products Regulatory Agency (MHRA). In this registration a manufacturer declares that their devices are safe and meet all of the relevant requirements of the legislation including having evidence to support their performance claims. For some higher risk devices a manufacturer has to have its product checked before it is placed on the market. Such checks are undertaken by third-party conformity assessment bodies called notified bodies.<\/p> <\/p> <\/p> <\/p> The role of the MHRA is to ensure that all medical devices placed on the UK market are compliant with the relevant legislation and to enforce this legislation on behalf of the Secretary of State. The MHRA fulfils this role by monitoring notified bodies (for higher risk devices) and operating the UK medical device vigilance system, which involves assessing and responding to safety concerns involving devices.<\/p> <\/p> <\/p> <\/p> The MHRA does not have a role in assessing the additional costs or benefits of devices to the National Health Service and so has not done so in the case of the service offered by 23andMe.<\/p> <\/p> <\/p> <\/p> Furthermore, under existing EU legislation, testing services are regulated in the country where the test is being performed. The tests offered by 23andMe are performed in laboratories that are based in the United States of America and as such are covered by US legislation.<\/p> <\/p> <\/p> <\/p> The Government has advised that no test will be 100% reliable, that 23andMe should be used with caution and that the information provided by 23andMe should not lead consumers to make any changes of medical significance, such as changes to medication, without first consulting their healthcare professional. If consumers need more information about the conditions listed in their results then they can visit the NHS Choices website for more information.<\/p> <\/p> <\/p> <\/p> The MHRA discussed the 23andMe Personal Genome Service with the US Food and Drug Administration (FDA) and shared information under the confidentiality commitment that is in place between the two agencies.<\/p> <\/p> <\/p> <\/p> The MHRA also held discussions with 23andMe prior to them launching their product in the UK. In those discussions, 23andMe explained that the product being offered in the UK is different to their US product in that many of the drug responses, inherited conditions and genetic health risks that were of concern to the FDA have been removed. 23andMe also presented results of surveys with UK-based consumers of their existing service that demonstrated that 4% of people had a specific conversation with their general practitioner (GP) as a result of their test results but it is not known how many GP visits led to National Health Service treatment.<\/p> <\/p> <\/p> <\/p> In the context of those discussions, the MHRA also agreed with 23andMe that they would take part in an enhanced surveillance program. Such a program involves regular sharing of safety information that might not otherwise meet the threshold for reporting to the competent authority. This will allow the MHRA to have a more in depth look at the performance of the test in use and if this highlights any regulatory or safety issues then they will consider further action.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
}
, "answeringMemberPrinted" : {"_value" : "Earl Howe"}
, "dateOfAnswer" : {"_value" : "2014-12-16", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "HL3343"}
, {"_value" : "HL3344"}
, {"_value" : "HL3345"}
, {"_value" : "HL3347"}
, {"_value" : "HL3348"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-12-16T14:44:44.437Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-12-02", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "DNA: Screening"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government what are the minimum standards required for a personal genome service to be approved by the Medicines and Healthcare Products Regulatory Agency.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4286", "label" : {"_value" : "Biography information for Lord Mendelsohn"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Mendelsohn"}
], "uin" : "HL3346"}
], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 6, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}